Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Detection of Oral and Throat Cancers Using OralViome Cancer Testing System

NCT05451303 · View on ClinicalTrials.gov ↗

Study Summary

To evaluate the design, safety and efficacy of OralViome Cancer Testing system in the early detection of Oral and Throat Cancers using saliva metatranscriptomic analysis. This study will recruit only at existing clinical sites and will NOT use any additional clinical sites.

Interventions

  • DEVICE OralViome Cancer Testing System

Study Locations (1)

New York

  • NYMC — New York

Trial Details

FieldValue
Enrollment Target 475 participants
Start Date 2022-05-27
Est. Completion 2026-12

Sponsor

Viome

43 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05451303

The ClinicalTrials.gov registry entry for NCT05451303 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 475 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viome, which has 43 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Oropharynx Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention — of which OralViome Cancer Testing System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05451303 reports 1 study location spanning 1 distinct geographic area — top geographies include New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05451303 about?

NCT05451303 is a clinical study titled "Detection of Oral and Throat Cancers Using OralViome Cancer Testing System". To evaluate the design, safety and efficacy of OralViome Cancer Testing system in the early detection of Oral and Throat Cancers using saliva metatranscriptomic analysis. This study will recruit only at existing clinical sites and will NOT use any additional clinical sites.

What is the current status of trial NCT05451303?

This trial is currently recruiting. The enrollment target is 475 participants. The study started on 2022-05-27. Estimated completion is 2026-12.

What conditions does trial NCT05451303 study?

This clinical trial studies the following conditions: Oropharynx Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Premalignant Lesion. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05451303?

The interventions under investigation include: OralViome Cancer Testing System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05451303?

This trial is sponsored by Viome, which has 43 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05451303 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial